While the data changes rapidly, we see the vaccine’s effectiveness from the perspective of protecting against COVID-19-related hospitalization at around 80% after a single dose of Johnson & Johnson vaccine. Protection remains at a constant level throughout the period that has been studied so far, i.e. up to 6 months, emphasized Dr. Mathai Mammen, Ph.D., vice president of the pharmaceutical division of Janssen Research & Development LLC, Johnson & Johnson.
– The durability of the protection of our vaccine reflects its basic immunological properties. As previously reported, our vaccine elicits a strong antibody response as well as an increase in T lymphocytes in the presence of all virus variants and therefore also the omicron variant, he added.
On the portal medRxiv A new study has been published that looks at the protection profiles of all three US-approved vaccines. The same methodology was used for all formulations for the following three parameters:
- infections that break COVID-19,
- admissions to intensive care units.
The study showed that the effectiveness of the Johnson & Johnson vaccine against COVID-19 in fighting breakthrough infections and protecting against hospitalization was stable for up to 6 months.
The mRNA (two-dose) vaccines showed declining efficacy in protecting against hospitalizations and breakthrough infections, with a single dose of Janssen against COVID-19 being less effective than that of the mRNA vaccine given in two doses.
We are glad that you are with us. Subscribe to the Onet newsletter to receive the most valuable content from us
Source: Janssen, medRxiv